

FabrÃ-cio A Moreira

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2789677/publications.pdf>

Version: 2024-02-01

67
papers

2,787
citations

236833

25
h-index

182361

51
g-index

68
all docs

68
docs citations

68
times ranked

3403
citing authors

#	ARTICLE	IF	CITATIONS
1	The endocannabinoid system and drug-associated contextual memories. <i>Behavioural Pharmacology</i> , 2022, 33, 90-104.	0.8	6
2	Anti-aversive effect of 2-arachidonoylglycerol in the dorsolateral periaqueductal gray of male rats in contextual fear conditioning and Vogel tests. <i>Behavioural Pharmacology</i> , 2022, 33, 213-221.	0.8	1
3	TRPV1 blockers as potential new treatments for psychiatric disorders. <i>Behavioural Pharmacology</i> , 2022, 33, 2-14.	0.8	11
4	The antipsychotic aripiprazole induces peripheral antinociceptive effects through PI3K β /NO/cGMP/K ⁺ ATP pathway activation. <i>European Journal of Pain</i> , 2022, 26, 825-834.	1.4	2
5	Exploiting cannabinoid and vanilloid mechanisms for epilepsy treatment. <i>Epilepsy and Behavior</i> , 2021, 121, 106832.	0.9	12
6	Protective role of endocannabinoid signaling in an animal model of haloperidol-induced tardive dyskinesia. <i>Pharmacology Biochemistry and Behavior</i> , 2021, 206, 173193.	1.3	4
7	Cannabidiol prevents lipopolysaccharide-induced sickness behavior and alters cytokine and neurotrophic factor levels in the brain. <i>Pharmacological Reports</i> , 2021, 73, 1680-1693.	1.5	5
8	Inhibition of CSF1R, a receptor involved in microglia viability, alters behavioral and molecular changes induced by cocaine. <i>Scientific Reports</i> , 2021, 11, 15989.	1.6	14
9	Role of cytokine and neurotrophic factors in nicotine addiction in the conditioned place preference paradigm. <i>Neuroscience Letters</i> , 2021, 764, 136235.	1.0	4
10	Effects of the monoamine stabilizer, (-)-OSU6162, on cocaine-induced locomotion and conditioned place preference in mice. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2021, 394, 1143-1152.	1.4	1
11	Systematic review and meta-analysis on the role of mitochondrial cytochrome c oxidase in Alzheimer's disease. <i>Acta Neuropsychiatrica</i> , 2021, 33, 55-64.	1.0	9
12	Effects of JL13, a pyridobenzoxazepine compound, in dopaminergic and glutamatergic models of antipsychotic activity. <i>Behavioural Pharmacology</i> , 2021, 32, 2-8.	0.8	2
13	Intravenous doxapram administration as a potential model of panic attacks in rats. <i>Behavioural Pharmacology</i> , 2021, 32, 182-193.	0.8	0
14	The roles of cannabinoid CB1 and CB2 receptors in cocaine-induced behavioral sensitization and conditioned place preference in mice. <i>Psychopharmacology</i> , 2020, 237, 385-394.	1.5	27
15	The Endocannabinoid System Activation as a Neural Network Desynchronizing Mediator for Seizure Suppression. <i>Frontiers in Behavioral Neuroscience</i> , 2020, 14, 603245.	1.0	11
16	Evaluation of Brain Cytokines and the Level of Brain-Derived Neurotrophic Factor in an Inflammatory Model of Depression. <i>NeuroImmunoModulation</i> , 2020, 27, 87-96.	0.9	8
17	Role of gut microbiota in the GBR12909 model of mania-like behavior in mice. <i>Journal of Neuroimmunology</i> , 2020, 346, 577292.	1.1	6
18	Opposing roles of CB ₁ and CB ₂ cannabinoid receptors in the stimulant and rewarding effects of cocaine. <i>British Journal of Pharmacology</i> , 2019, 176, 1541-1551.	2.7	36

#	ARTICLE	IF	CITATIONS
19	Hypothalamic endocannabinoid signalling modulates aversive responses related to panic attacks. <i>Neuropharmacology</i> , 2019, 148, 284-290.	2.0	11
20	Role of Endocannabinoid System in the Peripheral Antinociceptive Action of Aripiprazole. <i>Anesthesia and Analgesia</i> , 2019, 129, 263-268.	1.1	8
21	Cannabinoid CB1 receptors mediate the anxiolytic effects induced by systemic alprazolam and intra-periaqueductal gray 5-HT1A receptor activation. <i>Neuroscience Letters</i> , 2019, 703, 5-10.	1.0	5
22	Is there a role for cannabidiol in psychiatry?. <i>World Journal of Biological Psychiatry</i> , 2019, 20, 101-116.	1.3	31
23	Effects of the monoamine stabilizer (âˆš)-OSU6162 on locomotor and sensorimotor responses predictive of antipsychotic activity. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2018, 391, 761-768.	1.4	4
24	Inhibition of the dopamine transporter as an animal model of bipolar disorder mania: Locomotor response, neuroimmunological profile and pharmacological modulation. <i>Journal of Psychiatric Research</i> , 2018, 102, 142-149.	1.5	10
25	Effects of early or late prenatal immune activation in mice on behavioral and neuroanatomical abnormalities relevant to schizophrenia in the adulthood. <i>International Journal of Developmental Neuroscience</i> , 2017, 58, 1-8.	0.7	45
26	N-arachidonoyl-serotonin, a dual FAAH and TRPV1 blocker, inhibits the retrieval of contextual fear memory: Role of the cannabinoid CB1 receptor in the dorsal hippocampus. <i>Journal of Psychopharmacology</i> , 2017, 31, 750-756.	2.0	28
27	Reduced anxiety-like behavior in transgenic rats with chronically overproduction of angiotensin-(1â€“7): Role of the Mas receptor. <i>Behavioural Brain Research</i> , 2017, 331, 193-198.	1.2	39
28	2-Arachidonoylglycerol endocannabinoid signaling coupled to metabotropic glutamate receptor type-5 modulates anxiety-like behavior in the rat ventromedial prefrontal cortex. <i>Journal of Psychopharmacology</i> , 2017, 31, 740-749.	2.0	7
29	Anticonvulsant effect of cannabidiol in the pentylenetetrazole model: Pharmacological mechanisms, electroencephalographic profile, and brain cytokine levels. <i>Epilepsy and Behavior</i> , 2017, 75, 29-35.	0.9	82
30	Effects of alprazolam and cannabinoid-related compounds in an animal model of panic attack. <i>Behavioural Brain Research</i> , 2017, 317, 508-514.	1.2	6
31	Peripheral Antinociception Induced by Aripiprazole Is Mediated by the Opioid System. <i>BioMed Research International</i> , 2017, 2017, 1-6.	0.9	7
32	Anxiolytic- and antidepressant-like effects of angiotensin-(1â€“7) in hypertensive transgenic (mRen2)27 rats. <i>Clinical Science</i> , 2016, 130, 1247-1255.	1.8	34
33	Orchestrated activation of mGluR5 and CB1 promotes neuroprotection. <i>Molecular Brain</i> , 2016, 9, 80.	1.3	18
34	Effects of aripiprazole on caffeine-induced hyperlocomotion and neural activation in the striatum. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2016, 389, 11-16.	1.4	6
35	Role of endocannabinoid signalling in the dorsolateral periaqueductal grey in the modulation of distinct panic-like responses. <i>Journal of Psychopharmacology</i> , 2015, 29, 335-343.	2.0	14
36	Dopamine receptor partial agonists and addiction. <i>European Journal of Pharmacology</i> , 2015, 752, 112-115.	1.7	28

#	ARTICLE	IF	CITATIONS
37	Anti-aversive role of the endocannabinoid system in the periaqueductal gray stimulation model of panic attacks in rats. <i>Psychopharmacology</i> , 2015, 232, 1545-1553.	1.5	18
38	Involvement of TRPV1 channels in the periaqueductal grey on the modulation of innate fear responses. <i>Acta Neuropsychiatrica</i> , 2015, 27, 97-105.	1.0	12
39	Enhancement of endocannabinoid signaling protects against cocaine-induced neurotoxicity. <i>Toxicology and Applied Pharmacology</i> , 2015, 286, 178-187.	1.3	22
40	Endocannabinoids and striatal function. <i>Behavioural Pharmacology</i> , 2015, 26, 59-72.	0.8	35
41	Cannabidiol, a Cannabis sativa constituent, inhibits cocaine-induced seizures in mice: Possible role of the mTOR pathway and reduction in glutamate release. <i>NeuroToxicology</i> , 2015, 50, 116-121.	1.4	70
42	The antipsychotic aripiprazole induces antinociceptive effects: Possible role of peripheral dopamine D2 and serotonin 5-HT1A receptors. <i>European Journal of Pharmacology</i> , 2015, 765, 300-306.	1.7	21
43	Neuroinflammation as a possible link between cannabinoids and addiction. <i>Acta Neuropsychiatrica</i> , 2014, 26, 334-346.	1.0	18
44	A role for the endocannabinoid system in exercise-induced spatial memory enhancement in mice. <i>Hippocampus</i> , 2014, 24, 79-88.	0.9	58
45	Rimonabant effects on anxiety induced by simulated public speaking in healthy humans: a preliminary report. <i>Human Psychopharmacology</i> , 2014, 29, 94-99.	0.7	22
46	Inhibition of endocannabinoid neuronal uptake and hydrolysis as strategies for developing anxiolytic drugs. <i>Behavioural Pharmacology</i> , 2014, 25, 425-433.	0.8	33
47	The antipsychotic aripiprazole selectively prevents the stimulant and rewarding effects of morphine in mice. <i>European Journal of Pharmacology</i> , 2014, 742, 139-144.	1.7	20
48	Anticonvulsant Effects of N-Arachidonoylserotonin, a Dual Fatty Acid Amide Hydrolase Enzyme and Transient Receptor Potential Vanilloid Type-1 (TRPV1) Channel Blocker, on Experimental Seizures: The Roles of Cannabinoid CB1 Receptors and TRPV1 Channels. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2014, 115, 330-334.	1.2	20
49	Effects of compounds that interfere with the endocannabinoid system on behaviors predictive of anxiolytic and panicolytic activities in the elevated T-maze. <i>Pharmacology Biochemistry and Behavior</i> , 2013, 110, 33-39.	1.3	26
50	Effects of cannabinoids and endocannabinoid hydrolysis inhibition on pentylenetetrazole-induced seizure and electroencephalographic activity in rats. <i>Epilepsy Research</i> , 2013, 104, 195-202.	0.8	70
51	Modeling panic disorder in rodents. <i>Cell and Tissue Research</i> , 2013, 354, 119-125.	1.5	53
52	Effects of Aripiprazole, an Atypical Antipsychotic, on the Motor Alterations Induced by Acute Ethanol Administration in Mice. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2013, 112, 319-324.	1.2	22
53	Animal models for predicting the efficacy and side effects of antipsychotic drugs. <i>Revista Brasileira De Psiquiatria</i> , 2013, 35, S132-S139.	0.9	41
54	Opposing Roles for Cannabinoid Receptor Type-1 (CB1) and Transient Receptor Potential Vanilloid Type-1 Channel (TRPV1) on the Modulation of Panic-Like Responses in Rats. <i>Neuropsychopharmacology</i> , 2012, 37, 478-486.	2.8	97

#	ARTICLE	IF	CITATIONS
55	The endocannabinoid and endovanilloid systems interact in the rat prelimbic medial prefrontal cortex to control anxiety-like behavior. <i>Neuropharmacology</i> , 2012, 63, 202-210.	2.0	68
56	Cannabinoid type 1 receptors and transient receptor potential vanilloid type 1 channels in fear and anxiety – two sides of one coin?. <i>Neuroscience</i> , 2012, 204, 186-192.	1.1	92
57	Endocannabinoid system and psychiatry: in search of a neurobiological basis for detrimental and potential therapeutic effects. <i>Frontiers in Behavioral Neuroscience</i> , 2011, 5, 63.	1.0	101
58	Anti-aversive effects of the atypical antipsychotic, aripiprazole, in animal models of anxiety. <i>Journal of Psychopharmacology</i> , 2011, 25, 801-807.	2.0	27
59	The psychiatric side-effects of rimonabant. <i>Revista Brasileira De Psiquiatria</i> , 2009, 31, 145-153.	0.9	191
60	Cannabinoids and Anxiety. <i>Current Topics in Behavioral Neurosciences</i> , 2009, 2, 429-450.	0.8	146
61	Central side-effects of therapies based on CB1 cannabinoid receptor agonists and antagonists: focus on anxiety and depression. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2009, 23, 133-144.	2.2	229
62	Modulation of anxiety-like behaviour by Transient Receptor Potential Vanilloid Type 1 (TRPV1) channels located in the dorsolateral periaqueductal gray. <i>European Neuropsychopharmacology</i> , 2009, 19, 188-195.	0.3	90
63	Aripiprazole, an atypical antipsychotic, prevents the motor hyperactivity induced by psychotomimetics and psychostimulants in mice. <i>European Journal of Pharmacology</i> , 2008, 578, 222-227.	1.7	64
64	Reduced anxiety-like behaviour induced by genetic and pharmacological inhibition of the endocannabinoid-degrading enzyme fatty acid amide hydrolase (FAAH) is mediated by CB1 receptors. <i>Neuropharmacology</i> , 2008, 54, 141-150.	2.0	238
65	Lack of effects of clomipramine on Fos and NADPH-diaphorase double-staining in the periaqueductal gray after exposure to an innate fear stimulus. <i>Physiology and Behavior</i> , 2008, 94, 316-321.	1.0	9
66	Anxiolytic-like effect of cannabidiol in the rat Vogel conflict test. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2006, 30, 1466-1471.	2.5	168
67	Cannabidiol inhibits the hyperlocomotion induced by psychotomimetic drugs in mice. <i>European Journal of Pharmacology</i> , 2005, 512, 199-205.	1.7	164